Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian

Xiaoping Song1, Kailv Sun2, Jianming Hu1

  • 1Division of Gynecology and Obstetrics, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.

Oncology Letters
|April 29, 2016
PubMed

Insights

This study investigated human epidermal growth factor receptor 2 (HER2) in ovarian cancer. Suppressing HER2 with lentiviral-mediated small hairpin RNA (shRNA) increased chemotherapy sensitivity in ovarian cancer cells and xenografts.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The role of human epidermal growth factor receptor 2 (HER2) in ovarian carcinoma chemosensitivity remains incompletely understood.
  • HER2 is a known oncogene implicated in various cancers, but its specific function in ovarian cancer drug response requires further elucidation.

Purpose of the Study:

  • To investigate the potential role of HER2 in the chemosensitivity of ovarian carcinoma.
  • To determine if inhibiting HER2 expression can enhance the efficacy of chemotherapy in ovarian cancer models.

Main Methods:

  • Established stable HER2-knockdown (KD) SKOV3 ovarian cancer cell lines using lentiviral-mediated HER2-small hairpin RNA (shRNA).
  • Utilized reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot to confirm HER2 gene and protein suppression.
  • Assessed cell growth inhibition using a cell counting kit-8 assay and evaluated tumor growth in xenograft models treated with cisplatin (DDP).

Main Results:

  • Lentiviral-mediated HER2-shRNA significantly reduced HER2 mRNA and protein expression in SKOV3 cells (KD group) compared to control groups.
  • Suppression of HER2 expression led to increased chemosensitivity in ovarian cancer cells.
  • HER2 knockdown resulted in significantly slower tumor growth in vivo when treated with DDP chemotherapy.

Conclusions:

  • Lentivirus-mediated HER2-shRNA is an effective method for inhibiting HER2 gene expression in ovarian carcinoma.
  • Inhibiting HER2 expression enhances the chemosensitivity of ovarian cancer to cisplatin (DDP).
  • Targeting HER2 represents a potential therapeutic strategy to improve ovarian cancer treatment outcomes.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65